[Featured Stock] Syntekabio Hits Upper Limit on "Preclinical Efficacy Proven for Immuno-Oncology Drug Candidate"

[Asia Economy Reporter Ji Yeon-jin] Syntekabio, a drug development company based on genomic big data, surged to the daily limit on the 7th following news that its immune checkpoint inhibitor candidate demonstrated efficacy in preclinical animal models.

Syntekabio's stock price rose 29.71% (3,550 KRW) compared to the previous day, trading at 15,500 KRW just five minutes after the market opened.

Earlier, the company announced that the results of animal experiments for the immune checkpoint inhibitor candidate ‘STB-C017’, discovered by its AI-based drug candidate discovery platform Deepmatcher, were published online in the prestigious international immunology journal ‘OncoImmunology’.

According to the paper, when STB-C017 was orally administered alone to a mouse model implanted with colon cancer cell lines, tumor infiltration of ‘CD8+ T cells’, immune cells that attack cancer cells, increased, and changes in the expression patterns of immune-related genes were induced.

Furthermore, when STB-C017 was co-administered with two types of immune checkpoint inhibitors, it improved the tumor immune microenvironment and induced ‘complete remission’ (no cancer cells detected after treatment) in more than 60% of the treated mice, demonstrating its potential as a combination therapy with immune checkpoint inhibitors.

A Syntekabio official stated, “The notable effects of STB-C017 in animal models exemplify the performance and competitiveness of our AI platform Deepmatcher.”